Hello
in my institute for multi-dose container management we intended one bottle for specifically syrup for one patient e.g. DUPHALAC syrup every patient had one bottle, and not share one bottle for all patient (as recommendation from IPC Department) IT IS OK.
your advice appreciated in this issue
thank you

Hello,

In addition to dedicated pump and dedicated tubing, I am curious if any institutions have implemented other safety strategies for infusion and handling of epidural and oxytocin drips (eg. placement on opposite sides of the patient beds)?

We currently use the yellow CADD pumps with a lock box and infuse through with the yellow striped tubing.

Thank you,
Sonia Leon, PharmD, BCPS
Medication Safety Pharmacist

Does anyone have a policy they can share on the administration of IV Potassium Chloride to patients in asystole? We are considering one to spell out situations when a specifically trained intensivists may administer it as clinically indicated. Thank you in advance. -Melody Sun, CHOC Children's

If you have implemented IV pump and EHR integration, can you share any metrics that you measured to show improvement with use of integration?

We were discussing a few topics:
-improved I&O documentation especially with Sepsis patients
-decrease in reprogramming attempts by the nurse compared to pre go live practices
-incorrect programming compared to the Epic order (event reports)

(our pumps are the Plum 360 pumps from ICU medical and we use Epic)

TIA for your feedback:)

Here at Nicklaus Children's Hospital we are in the research phase of creating an antivenin pathway and PowerPlan. Do any other hospitals have a pathway that they have developed and are willing to share?

Thank you!

Kristen Post
Medication Safety Officer
Kristen.post@nicklaushealth.org

We are investigating if we can switch over our Epoprostenol and Treprostinil infusions from CADD Legacy 1 pumps to Baxter Spectrum IQ smart pumps. Has anyone done this and are you rounding rates per hour to the nearest tenths place?

Hi all,

I know this has been a frequent discussion topic for years, but my institution is once again reviewing our practices for IVPB medications given on primary vs. secondary line. My nursing colleagues are soliciting input on the following question:

When giving small-volume IVPBs (~50 mL or less) on a secondary line, after infusion is complete, there may be some residual drug in the secondary line. What is your procedure when IVPB has completed infusing? Do you flush the residual? What do you flush with? Do you have orders entered for this flush in your EHR or not?

For those sites using BD Alaris pumps, has your organization opted to move forward with the System software update (to v12.1.2) ahead of official FDA clearance? If so, is your organization planning any sort of specific surveillance of these devices?

Appreciate your insight!

Don't forget to visit the MSOS website to sign up for our upcoming Member Briefing webinar on Thursday, January 27th.

Safeguards around adult use of continuously inhaled epoprostenol
Sammy Burton, PharmD, FISMP
Cleveland Clinic

Utilizing the EMR to assure safe paralytic infusion practices
Mara Weber, PharmD
OhioHealth

Multi-chamber bag parenteral nutrition
Andrew Mays, PharmD
ASPEN PN Safety Committee

ISMP Update
Mike Cohen

Does anyone have benchmarks related to % Encounters with ADE and/or ADEs/1000 Admins that you are willing to share? Thanks in advance!